IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.69
3.69
Jahresspanne
2.82
5.81
Tagesänderung
-4.16%
Monatliche Änderung
-4.16%
6 month change
-9.56%
Jahresänderung
-0.81%
Vorheriger Schlusskurs
3.8 5
Open
3.6 9
Tief
3.6 9
Hoch
3.6 9
Volumen
59
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 10 March 2020

Full document

Business Context and Reporting Period

This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on March 10, 2020. The report details a material definitive agreement entered into on the same date with BioSense Global LLC regarding the company's drug candidate RX-3117.

Key Financial Metrics

This filing does not provide standard financial statements such as revenue, profit, cash flow, or debt levels. The only specific financial figures disclosed relate to the amended agreement:

  • Upfront Payments: Reduced to an aggregate of $1.65 million ($1.5 million previously paid).
  • Milestone Payments: Eligible to receive up to $74.5 million upon achieving development, regulatory, and commercial goals.
  • Royalties: Tiered royalties in the mid-single digits to low tens on annual net sales in the Territory.

Material Changes

The company amended its February 2019 Collaboration and License Agreement with BioSense Global LLC. Key changes include:

  • Termination of Collaboration: Rexahn will not conduct or sponsor additional trials with RX-3117.
  • Scope Reduction: Collaboration provisions were removed; the agreement is now a License and Assignment Agreement.
  • Financial Adjustments: Upfront payments were reduced, and milestone payments and royalties were lowered compared to the original agreement.
  • Asset Transfer: Upon full payment, Rexahn will assign all patents related to RX-3117 in the Territory (Singapore, China, Hong Kong, Macau, and Taiwan) to BioSense.

Outlook, Risks, and Management Commentary

Management has indicated a strategic shift to exit the development phase for RX-3117, transferring those responsibilities to BioSense. BioSense has agreed to use commercially reasonable efforts to develop the product and file an investigational new drug application in China. A risk factor noted is the reduction in potential future revenue streams due to the lowered milestone and royalty structures. Additionally, BioSense holds an option until March 31, 2020, to expand the exclusive license outside the defined Territory for an additional fee.

Investor Verification Checklist

  • Verify the exact amount of the remaining unpaid upfront portion of the $1.65 million total.
  • Confirm the specific tiered royalty percentages defined in the full text of the Amendment.
  • Monitor whether BioSense exercises the option to expand the license territory before March 31, 2020.
  • Review the full text of the Amendment filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2020.